Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report

Journal of Gastrointestinal Cancer · Published 2026-08-01 · DOI 10.1007/s12029-026-01553-4

Authors (7)

Yuki Yamasaki, Kentaro Miyazaki, Yuta Fujiwara, Yukari Yamaguchi, Keishi Nakamura, Kaname Ishii, Katsunobu Oyama

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Yamasaki, Y., Miyazaki, K., Fujiwara, Y., et al. (2026). Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-026-01553-4

Related articles

• Characteristics and Outcomes of Patients With Malignancies Prior to Colorectal Cancer: A Propensity Score Matched Analysis · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: a Single-Center Retrospective Study · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Trends in Pancreatic Cancer Incidence, Mortality and Net Survival: A Population-Based Analysis in Zurich (Switzerland), 1981–2021 · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Access or Engagement: The Potential Role of Financial Incentives in Colorectal Cancer Screening · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Comment on “Efficacy of Radiotherapy Combined with Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer: A Propensity-Matched Retrospective Study” · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Who Truly Benefits from Anti-EGFR Rechallenge in Metastatic Colorectal Cancer? From Clinical Enrichment to ctDNA-Guided Molecular Hyperselection · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Gastric Cancer Incidence in Iran: Trends and Projections to 2030 based on Global Burden of Disease 2021 Estimates · Journal of Gastrointestinal Cancer · 2026 · Same journal
• Redefining First-Line HER2-Positive Advanced Gastric Cancer: From Trastuzumab-Based Chemoimmunotherapy to Zanidatamab and Next-Generation HER2 Targeting · Journal of Gastrointestinal Cancer · 2026 · Same journal